Analyst Research Report Snapshot

Title:

MabCure Inc. (MBCI) - Financial Analysis Review

Price:

$125.00

Provider:

GlobalData

Date:

19 Dec 2012

Pages:

30

Type:

AcrobatPDF

Companies referenced:

MPL.LM

Available for Immediate Download
Summary:

MabCure Inc. (MBCI) - Financial Analysis Review Summary MabCure Inc. (MabCure) is a biotechnology company, based in the US. The company develops monoclonal antibodies for the in-vitro diagnostic markets. It develops novel molecular antibodies as diagnostic tools for the detection of prostate and ovarian cancers at an early stage. The company also develops new technologies for the early detection of cancer as well antibodies and drugs that attacks on cancer cells. GlobalData's MabCure Inc. (MBCI) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years. MabCure Inc. Key Recent Developments: Apr 16, 2012: MabCure Reports 2011 Results Mar 19, 2012: MabCure Partners With City University of New York Center for Advanced Technology To Validate And Evaluate Its Monoclonal Antibodies As Ovarian Cancer Diagnostic Reagents Nov 21, 2011: MabCure Reports Q3 2011 Results Aug 22, 2011: MabCure Reports Q2 2011 Results May 23, 2011: MabCure Reports Q1 2011 Results This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope - Business description - A detailed description of the company's operations and business divisions. - Company history - Progression of key events associated with the company. - Major products and services - A list of major products, services and brands of the company. - Key competitors - A list of key competitors to the company. - Key employees - A list of the key executives of the company. - Executive biographies - A brief summary of the executives' employment history. - Key operational heads - A list of personnel heading key departments/functions. - Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details. - Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Note: Some sections may be missing if data is unavailable for the company. Reasons to Buy - Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. - Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services. - Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.